October 12, 2018 News by Jose Marques Lopes, PhD #ECTRIMS2018: Study Proposes Serum Neurofilament Light Threshold to Identify RRMS Patients at Risk of Worsening Relapsing-remitting multiple sclerosis (RRMS) patients with serum neurofilament light chain (sNfL) levels higher than a proposed threshold have a higher risk of disease activity, and worsened disability, lesions and brain shrinkage in the long term, according to a new study. The research, āSerum neurofilament light (NfL)…
September 5, 2018 News by Patricia Inacio, PhD Higher Levels of Neurofilament Light Chain in Blood and Cerebrospinal Fluid Found in MS Patients, Supporting its Prognostic Potential A meta-analysis of 13 case-control studies shows that the levels of the protein neurofilament light chain (NFL) are significantly higher in both the cerebrospinal fluid and blood of multiple sclerosis (MS) patients, compared to healthy controls. This findingĀ adds to previous evidence supporting the usefulness of NFL as a…
August 8, 2018 News by Alice MelĆ£o, MSc Quanterixās Simoa Assay May Make Neurofilament Light Chain Useful Blood Biomarker of MS and Its Likely Progression Quanterixās ultra-sensitive Simoa assay has the potential to open new uses for the brain biomarker known as neurofilament light chain, including the possibility to detect early evidence of neurological diseases like multiple sclerosis (MS),Ā Parkinsonās, and Alzheimerās, and ably evaluate efforts to treat and prevent them,Ā the company…
July 24, 2018 News by Ana Pena PhD Cerebrospinal Fluid Neurofilament Predicts CIS and RRMS Progression, Study Contends Cerebrospinal fluid levels of neurofilament light chain, a protein associated with nerve cell damage, can predict disease progression in people with clinical isolated syndrome (CIS) and relapsing-remitting multiple sclerosis (RRMS), a Swedish study found. Higher levels…
July 17, 2018 News by Alice MelĆ£o, MSc Progressive MS Patients with Considerable Disability Ably Treated with Cladribine, UK Case Study Reports Cladridine may be effective in preventingĀ disability progression and reducing damage to nerve cells in people withĀ progressive forms of multiple sclerosis (MS), researchers suggest based on a case study of two such patients given the injectable treatment. MS is characterized by progressive degeneration of cells in the central nervous system, mostly…
June 20, 2018 News by Patricia Inacio, PhD #EAN2018 – Levels ofĀ Neurofilament Light Chain Can Predict Disease Progression in RRMS, Study Shows Levels ofĀ neurofilament light chain are a reliable predictor of disease worsening and progression in relapsing-remitting MS (RRMS) patients, a new study shows. Moreover, treatment withĀ GilenyaĀ (fingolimod), marketed by Novartis, can reduce the levels ofĀ NfL for up to 10 years. These findings were shared recently in the presentation ā…
April 23, 2018 News by Alice MelĆ£o, MSc #AAN2018 ā Neurofilament Light Blood Levels Can Help Define Disease Activity in RRMS, Study Shows Analysis of a potential blood biomarker linked to brain cell damage can help define disease activity in patients with relapsing-remitting multiple sclerosis (RRMS). Results of a study showed that determining blood levels of neurofilament light chain, or NfL, could help in establishing āno evidence of disease activity,ā or NEDA, status…
April 19, 2018 News by Patricia Inacio, PhD #AAN2018 – Biogen Data Covers Work into an MS Blood Biomarker, Cognition and Life Quality Research that points to aĀ potential blood biomarker ofĀ multiple sclerosis (MS) severity, relates cognitive difficulties to patients’ employment and other measures of socioeconomic status, and one-year results of an ongoing clinical trial are among data presentations planned byĀ BiogenĀ for theĀ annual meeting of the American Academy of Neurology (AAN). This year’s…
April 18, 2018 News by Alice MelĆ£o, MSc #AAN2018 ā Levels of Protein Derived from Brain Cell Damage Can Mirror Severity of MS, Study Finds Levels of a protein stemming from brain cell damage can mirror the severity and symptoms of multiple sclerosis, an analysis of combined data from three trials showed. Researchers will present this and related findingsĀ at the annual meeting of the American Academy of NeurologyĀ in Los Angeles, April 21-27. The…
April 18, 2018 News by Patricia Inacio, PhD #AAN2018 – Ocrevus Decreases Biomarkers of MS Patients’ Nerve Cell Damage, Phase 3 Trial Shows Genentech’sĀ Ocrevus (ocrelizumab)Ā reduces levels of cerebrospinal fluid biomarkers that denote nerve cell damage in multiple sclerosis patients, a Phase 3 clinical trial shows. Researchers will present the results at theĀ American Academy of Neurology’s annual meetingĀ in Los Angeles, April 21-27. The presentation will be titled āInterim Analysis of the…
April 17, 2018 News by Alice MelĆ£o, MSc #AAN2018 ā Siponimod Reduces Disease Activity Biomarker in SPMS Patients Novartis‘ siponimod (BAF312) can reduce blood levels of a biomarker of nerve cell damage in patients with secondary progressive multiple sclerosis (SPMS), a Phase 3 clinical trial shows. Researchers will present the latest results of the ongoing trial at the 2018 annual meeting of the American Academy…
December 13, 2017 News by Patricia Silva, PhD Levels of Nerve Protein in Blood Provide Good Grasp of MS Activity, Study Finds Blood levels of the nerve damage marker neurofilament light provide a reliable picture of multiple sclerosis activity in both the relapsing-remitting and progressive forms of the disease,Ā a Swedish study reports. TheĀ University of GothenburgĀ researchers also discovered a close link between its levels in blood and spinal fluid. This means the…